Current Edition

Adjuvanted Seasonal Influenza Vaccine Development

In this article, Walter Chalkley, Senior Editorial Project Manager for Cortellis Regulatory Intelligence, outlines the current situation with regard to the use of adjuvants in the influenza vaccine. Often, especially when a patient’s immune system is naive (as in paediatric patients) or undergoing senescence (the aging of the immune system in elderly patients), a heightened immune response is needed for a vaccine to have the desired effect. The addition of adjuvants to a vaccine is one way of doing this. The author explains that an adjuvanted seasonal influenza vaccine would be a major step in the US and that, despite the general concerns about adjuvants, developers see this area of unmet need as a potentially viable field of investigation.….pdf